PLXNB1

Across TCGA pan-cancer cohorts, PLXNB1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLXNB1 data layer compared with 26 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLXNB1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLXNB1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where PLXNB1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.675	0.897	.005	19	view →
HNSC	DFS	Median	All	0.291	1.000	.001	16	view →
LSCC	DFS	Median	III,IV	0.938	0.453	.003	16	view →
LUAD	DFS	Median	III,IV	0.553	0.928	.011	11	view →
CCRCC	OS	Quartile	All	1.000	0.886	.017	5	view →
GBM	DFS	Tertile	All	0.282	0.559	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLXNB1–PDAC (DFS)

Open the PDAC breakdown →